Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

FLT3-ITD mutations occur in 20–30% of AML patients and are associated with aggressive disease. Patients with relapsed FLT3-mutated disease respond well to 2(nd) generation FLT3 TKIs but inevitably relapse within a short timeframe. In this setting, until overt relapse occurs, the bone marrow microenv...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ami B., Pomicter, Anthony D., Yan, Dongqing, Eiring, Anna M., Antelope, Orlando, Schumacher, Jonathan A., Kelley, Todd W., Tantravahi, Srinivas K., Kovacsovics, Tibor J., Shami, Paul J., O’Hare, Thomas, Deininger, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606260/
https://www.ncbi.nlm.nih.gov/pubmed/32409689
http://dx.doi.org/10.1038/s41375-020-0858-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606260/
https://www.ncbi.nlm.nih.gov/pubmed/32409689
http://dx.doi.org/10.1038/s41375-020-0858-1

Ejemplares similares